Joshua R. Vest
Alnylam Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Electronic Health Records Systems, Amyloidosis: Diagnosis, Treatment, Outcomes, Healthcare Systems and Technology, Healthcare Policy and Management, Primary Care and Health Outcomes
Most-Cited Works
- → FKBP12.6 Deficiency and Defective Calcium Release Channel (Ryanodine Receptor) Function Linked to Exercise-Induced Sudden Cardiac Death(2003)753 cited
- → Protection from Cardiac Arrhythmia Through Ryanodine Receptor-Stabilizing Protein Calstabin2(2004)474 cited
- → Risk factors for surgical site infection in spinal surgery(2003)473 cited
- → Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis(2019)458 cited
- → Health information exchange: persistent challenges and new strategies: Table 1(2010)388 cited
- → Ryanodine receptor/calcium release channel PKA phosphorylation: A critical mediator of heart failure progression(2006)364 cited
- → Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation(2005)352 cited
- → Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial(2022)351 cited
- → Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy(2024)301 cited
- → β-Blockers Restore Calcium Release Channel Function and Improve Cardiac Muscle Performance in Human Heart Failure(2003)300 cited